JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$6.20
1.03 (19.92%)
▲
5d:
+18.32%
30d:
+3952.29%
90d:
+2189.51%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 17, 2026
0d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: JUNS is 39.0% above its trading range ($4.46). Market expects 98.7% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: JUNS is 39.0% above its trading range ($4.46). Market expects 98.7% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $6.20, which is considered extended relative to its 30-day fair value range of $-0.47 to $4.46. From a valuation perspective, the stock is trading at a premium (Forward PE: 103.3) compared to its historical average (13.2). At these levels, the market is pricing in 98.7% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, JUNS is in a uptrend. Immediate support is located at $4.56, while resistance sits at $11.20. The stock is showing strong short-term momentum, up 19.9% recently.
Market Sentiment: JUNS scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+383.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JUNS is in a uptrend. Immediate support is located at $4.56, while resistance sits at $11.20. The stock is showing strong short-term momentum, up 19.9% recently.
Market Sentiment: JUNS scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $30.00 (+383.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$-0.47 -
$4.46
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price significantly overextended (+39.0% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+19.9%)
- BULLISH: Trading 383.9% below Wall St target ($30.00)
- BEARISH: Market expects 98.7% growth - appears too optimistic based on history
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.47 -
$4.46
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.56
Resistance Level
$11.20
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
103.33
Wall Street Target
$30.00
(+383.9%)
Valuation Premium vs History
+98.7% premium
PE vs Historical
103.3 vs 13.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+98.7%
(market-implied from PE analysis)
1-Year Target
$9.30
(+50%)
2-Year Target
$13.95
(+125%)
3-Year Target
$20.93
(+238%)
3-Yr Target (if PE normalizes)
(PE: 103→13)
PE COMPRESSION
$2.67
(-57%)
Significant PE compression expected
Share & Embed Analysis
Last updated: August 24, 2026 3:38 AM ET
Data refreshes hourly during market hours. Next update: 4:38 AM
Data refreshes hourly during market hours. Next update: 4:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
